Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
Authors
McEvoy, Lynda MO'Toole, Sharon A
Spillane, Cathy D
Martin, Cara M
Gallagher, Michael F
Stordal, Britta
Blackshields, Gordon
Sheils, Orla
O'Leary, John J
Issue Date
2015Keywords
CANCER, OVARIANMeSH
AngiopoietinsAntineoplastic Agents
Biomarkers, Tumor
Cell Hypoxia
Cell Line, Tumor
Cisplatin
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
Ovarian Neoplasms
Receptor, ErbB-3
Metadata
Show full item recordCitation
Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer. 2015, 15:547 BMC CancerPublisher
SpringerJournal
BMC cancerDOI
10.1186/s12885-015-1539-8PubMed ID
26205780Abstract
Ovarian cancer is associated with poor long-term survival due to late diagnosis and development of chemoresistance. Tumour hypoxia is associated with many features of tumour aggressiveness including increased cellular proliferation, inhibition of apoptosis, increased invasion and metastasis, and chemoresistance, mostly mediated through hypoxia-inducible factor (HIF)-1α. While HIF-1α has been associated with platinum resistance in a variety of cancers, including ovarian, relatively little is known about the importance of the duration of hypoxia. Similarly, the gene pathways activated in ovarian cancer which cause chemoresistance as a result of hypoxia are poorly understood. This study aimed to firstly investigate the effect of hypoxia duration on resistance to cisplatin in an ovarian cancer chemoresistance cell line model and to identify genes whose expression was associated with hypoxia-induced chemoresistance.Item Type
ArticleLanguage
enISSN
1471-2407ae974a485f413a2113503eed53cd6c53
10.1186/s12885-015-1539-8
Scopus Count
Collections
Related articles
- SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α.
- Authors: Ao Q, Su W, Guo S, Cai L, Huang L
- Issue date: 2015 Nov 9
- Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
- Authors: Ai Z, Lu Y, Qiu S, Fan Z
- Issue date: 2016 Apr 1
- Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
- Authors: Zhang X, Qi Z, Yin H, Yang G
- Issue date: 2019
- Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
- Authors: Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E
- Issue date: 2007 Jul 15
- Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
- Authors: Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, Yu J
- Issue date: 2006 Dec